Molecular genetic and cytogenetic determinants of primary resistance or loss of the response to treatment with tyrosine kinase inhibitors in patients with chronic myeloid leukemia.

by Kotlyarchuk K., Maslyak Z., Lukianova A., Tsyapka O., Selina I., Usenko A.
Published 2015-09-01

Standard of care and direct medical costs of the treatment of chronic lymphocytic leukemia among the adult population in Ukraine, Russia, and Kazakhstan: data from the LEUKOSPECT s...

by Vasylyev A, Molostvova V, Rebrov BA, Makarova J, Zaritskey A, Ptushkin V, Ramazanova R, Popovych Y, Tsyapka O, Pashanov E
Published 2017-09-01